Two new experimental treatments against advanced melanoma have shown promise in keeping the deadly skin cancer at bay, according to research presented in the United States on Monday. The agents, known as Dabrafenib and Trametinib, are being developed by the British pharmaceutical firm GlaxoSmithKline, and were tested in clinical trials against standard chemotherapy treatments. The…